In addition, recent studies suggested that CHD4 has a potential to be a prognostic biomarker in triple-negative breast cancer 26, 35 and high CHD4 and 8-hydroxy-deoxyguanosine levels as well as low expression of TSGs were strongly correlated with early disease recurrence and decreased overall survival in CRC patients 21. This evidence concerns the gene CHD4 and colorectal carcinoma.